scholarly journals OP0311 THE ROLE OF COMORBID PATHOLOGY IN THE PROGRESSIVE COURSE OF ANCA-ASSOCIATED SYSTEMIC VASCULITIS

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 191.3-191
Author(s):  
A. Chudinov ◽  
I. Belyaeva ◽  
V. Mazurov ◽  
O. Inamova

Background:ANCA-associated systemic vasculitis (AAV) is characterized by a high incidence of complications and high damage index. Comorbid pathology at the onset can significantly worsen the prognosis AAV. The most significant comorbid conditions in patients with AAV are coronary artery disease, hypertension and dyslipidemia.Objectives:The aim of this study was to determine the role of comorbid pathology in the progressive course in patients with AAV.Methods:Patients with granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) were observed during the first 3 years of the disease and included in this study between 2010 and 2018. At the onset of AAV 75% of patients had significant comorbidities (coronary artery disease, hypertension, dyslipidemia, chronic obstructive pulmonary disease, peptic ulcer, diabetes mellitus, autoimmune thyroiditis and others).Results:In total 209 (165 [79%] female and mean age 51.8 ± 13.2 years) AAV patients (94 GPA; 46 MPA; and 69 EGPA) were included in the analysis. Formation of chronic kidney disease was significantly more frequent in the group of AAV patients with hypertension at the onset, than in patients without hypertension (respectively 37% and 23.6%, p=0.041). Development of thromboembolic complications was significantly more frequent in the group of AAV patients with coronary artery disease at the onset of AAV, than in patients without coronary artery disease (respectively 34% and 14.8%, p=0.034). Dyslipidemia also was risk factor for cardiovascular complications (OR – 3.81, 95% CI (2.43; 8.2) p=0.009). Presence of diabetes mellitus in the AAV onset was risk factor for infectious complications (OR – 1.77, 95% CI (1.14; 3.45) p=0.038).Conclusion:Our study has shown that comorbid pathology increase risk of serious complications and can significantly worsen the prognosis AAV. Prevention of development of comorbid conditions and control of lipid levels, hypertension levels are necessary to prevent the formation of irreversible organ damage.Disclosure of Interests:None declared.

2017 ◽  
Vol 8 ◽  
Author(s):  
Lidia Sanchez-Alcoholado ◽  
Daniel Castellano-Castillo ◽  
Laura Jordán-Martínez ◽  
Isabel Moreno-Indias ◽  
Pilar Cardila-Cruz ◽  
...  

Circulation ◽  
2020 ◽  
Vol 141 (19) ◽  
Author(s):  
Suzanne V. Arnold ◽  
Deepak L. Bhatt ◽  
Gregory W. Barsness ◽  
Alexis L. Beatty ◽  
Prakash C. Deedwania ◽  
...  

Although cardiologists have long treated patients with coronary artery disease (CAD) and concomitant type 2 diabetes mellitus (T2DM), T2DM has traditionally been considered just a comorbidity that affected the development and progression of the disease. Over the past decade, a number of factors have shifted that have forced the cardiology community to reconsider the role of T2DM in CAD. First, in addition to being associated with increased cardiovascular risk, T2DM has the potential to affect a number of treatment choices for CAD. In this document, we discuss the role that T2DM has in the selection of testing for CAD, in medical management (both secondary prevention strategies and treatment of stable angina), and in the selection of revascularization strategy. Second, although glycemic control has been recommended as a part of comprehensive risk factor management in patients with CAD, there is mounting evidence that the mechanism by which glucose is managed can have a substantial impact on cardiovascular outcomes. In this document, we discuss the role of glycemic management (both in intensity of control and choice of medications) in cardiovascular outcomes. It is becoming clear that the cardiologist needs both to consider T2DM in cardiovascular treatment decisions and potentially to help guide the selection of glucose-lowering medications. Our statement provides a comprehensive summary of effective, patient-centered management of CAD in patients with T2DM, with emphasis on the emerging evidence. Given the increasing prevalence of T2DM and the accumulating evidence of the need to consider T2DM in treatment decisions, this knowledge will become ever more important to optimize our patients’ cardiovascular outcomes.


2014 ◽  
Vol 15 (3) ◽  
pp. 257-264 ◽  
Author(s):  
Gehan Hamdy ◽  
Olfat M. Hendy ◽  
Hala Mahmoud ◽  
Azza El-sebaey ◽  
Salwa R. Ali ◽  
...  

1998 ◽  
Vol 41 (1) ◽  
pp. 45-48 ◽  
Author(s):  
Mikihiko Kawano ◽  
Masaki Shinomiya ◽  
Tetsuto Kanzaki ◽  
Nobubiro Morisaki ◽  
Kohji Shirai ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document